bluebird bio, Inc. (NASDAQ:BLUE) – Stock analysts at Cantor Fitzgerald lowered their FY2017 earnings per share (EPS) estimates for shares of bluebird bio in a research note issued to investors on Wednesday. Cantor Fitzgerald analyst E. Piros now expects that the biotechnology company will post earnings per share of ($7.15) for the year, down from their prior estimate of ($6.52). Cantor Fitzgerald has a “Sell” rating and a $39.00 price objective on the stock. Cantor Fitzgerald also issued estimates for bluebird bio’s FY2018 earnings at ($7.85) EPS.

bluebird bio (NASDAQ:BLUE) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. During the same quarter in the prior year, the company posted ($1.59) EPS. bluebird bio’s revenue was up 977.4% compared to the same quarter last year.

TRADEMARK VIOLATION WARNING: “FY2017 Earnings Forecast for bluebird bio, Inc. (BLUE) Issued By Cantor Fitzgerald” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/30/fy2017-earnings-forecast-for-bluebird-bio-inc-blue-issued-by-cantor-fitzgerald.html.

A number of other analysts have also recently commented on BLUE. Maxim Group reiterated a “hold” rating on shares of bluebird bio in a research report on Friday, May 5th. Morgan Stanley lifted their price objective on bluebird bio from $87.00 to $91.00 and gave the stock an “equal weight” rating in a research report on Monday, May 8th. Zacks Investment Research upgraded bluebird bio from a “sell” rating to a “hold” rating in a research report on Monday, May 8th. Standpoint Research started coverage on bluebird bio in a research report on Tuesday, May 30th. They set a “buy” rating and a $110.00 price objective for the company. Finally, BTIG Research reiterated a “buy” rating and set a $112.00 price objective on shares of bluebird bio in a research report on Thursday, June 1st. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $100.74.

bluebird bio (BLUE) opened at 102.40 on Monday. The company’s market cap is $4.67 billion. bluebird bio has a 12 month low of $37.05 and a 12 month high of $123.75. The company’s 50 day moving average is $95.59 and its 200-day moving average is $91.76.

In other news, insider Philip D. Gregory sold 1,500 shares of bluebird bio stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $99.04, for a total value of $148,560.00. Following the transaction, the insider now directly owns 37,279 shares of the company’s stock, valued at approximately $3,692,112.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Davidson sold 1,000 shares of bluebird bio stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $90.00, for a total value of $90,000.00. Following the completion of the transaction, the insider now directly owns 18,177 shares in the company, valued at $1,635,930. The disclosure for this sale can be found here. Insiders sold a total of 78,106 shares of company stock valued at $8,148,358 in the last 90 days. 3.90% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the stock. FMR LLC raised its position in bluebird bio by 9.6% in the second quarter. FMR LLC now owns 6,713,949 shares of the biotechnology company’s stock valued at $705,301,000 after buying an additional 587,236 shares in the last quarter. Capital Research Global Investors raised its position in bluebird bio by 9.9% in the second quarter. Capital Research Global Investors now owns 5,483,117 shares of the biotechnology company’s stock valued at $576,001,000 after buying an additional 493,072 shares in the last quarter. Baillie Gifford & Co. raised its position in bluebird bio by 3.8% in the second quarter. Baillie Gifford & Co. now owns 5,400,658 shares of the biotechnology company’s stock valued at $567,339,000 after buying an additional 196,025 shares in the last quarter. Vanguard Group Inc. raised its position in bluebird bio by 10.7% in the second quarter. Vanguard Group Inc. now owns 3,559,102 shares of the biotechnology company’s stock valued at $373,884,000 after buying an additional 343,856 shares in the last quarter. Finally, BlackRock Inc. raised its position in bluebird bio by 4.3% in the second quarter. BlackRock Inc. now owns 3,320,329 shares of the biotechnology company’s stock valued at $348,801,000 after buying an additional 138,141 shares in the last quarter.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Stock Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related stocks with our FREE daily email newsletter.